Keyphrases
High Density
100%
Antiangiogenic Agents
100%
Integrin
100%
Neovascularization
100%
Therapeutic Efficacy
14%
Retina
14%
Current Treatment
14%
Blood Vessels
14%
Retinopathy of Prematurity
14%
Angiogenic
14%
Adverse Effects
14%
Biological Effects
14%
Inhibitory Effect
14%
Treatment Options
14%
Physiological Processes
14%
Blindness
14%
Proliferation Inhibition
14%
Bioactive Peptides
14%
Diabetic Retinopathy
14%
Age-related Macular Degeneration
14%
Controlled Delivery
14%
Possible Treatments
14%
Invasive Procedures
14%
Nanoparticle Surface
14%
Dose Effect
14%
Vision Impairment
14%
Retinal Detachment
14%
Delivery Vehicle
14%
Tube Formation Assay
14%
Conjugation
14%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
14%
Abnormal Growth
14%
Antibody Therapy
14%
Maximum Inhibition
14%
Valency
14%
Human Umbilical Vein Endothelial Cells (HUVECs)
14%
Treatment Alternatives
14%
Vascular Endothelial Growth Factor Antibody
14%
Endophthalmitis
14%
Migration Inhibition
14%
Anti-VEGF Antibody
14%
Primary Endothelial Cells
14%
Surface Display
14%
Peptide Construct
14%
High Inhibition
14%
Higher-valency
14%
VEGF Vascular Endothelial Growth Factor
14%
Intravitreal Administration
14%
Lipidated Peptide
14%
Pharmacology, Toxicology and Pharmaceutical Science
Antiangiogenic
100%
Integrin
100%
Neovascularization (Pathology)
100%
Micelle
100%
Vasculotropin
28%
Vasculotropin Antibody
28%
Nanoparticle
14%
Retrolental Fibroplasia
14%
Side Effect
14%
Visual Impairment
14%
Age Related Macular Degeneration
14%
Retina Detachment
14%
Combination Therapy
14%
Diabetic Retinopathy
14%
Intravitreal Administration
14%
Endophthalmitis
14%
Diseases
14%